近日,德国 默克 宣布终止与 恒瑞医药 (600276)围绕PARP1抑制剂HRS-1167的全球授权合作。2023年,两者曾就HRS-1167达成授权协议,默克将获得恒瑞医药自研管线HRS-1167在中国大陆以外全球范围的独家开发、生产与商业化权利。但由于战略自身调整,默克打算收缩管线,将精力放在其他核心资源上。虽然这笔交易告吹,但恒瑞医药已获得的1.6亿欧元首付款无需退还。大单告吹2023年...
Source Link近日,德国 默克 宣布终止与 恒瑞医药 (600276)围绕PARP1抑制剂HRS-1167的全球授权合作。2023年,两者曾就HRS-1167达成授权协议,默克将获得恒瑞医药自研管线HRS-1167在中国大陆以外全球范围的独家开发、生产与商业化权利。但由于战略自身调整,默克打算收缩管线,将精力放在其他核心资源上。虽然这笔交易告吹,但恒瑞医药已获得的1.6亿欧元首付款无需退还。大单告吹2023年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.